Insulin thermostability in a real-world setting
- PMID: 37003280
- DOI: 10.1016/S2213-8587(23)00028-1
Insulin thermostability in a real-world setting
Conflict of interest statement
JM and GDO work for the Life for a Child programme at Diabetes NSW & ACT, which does receive non-salary support from Eli Lilly. MAA reports cooperation (consultative, educational, and research) with companies and entities (CodeBio, Diamyd Medical, Endsulin, IM therapeutics, and Repitoire) interested in type 1 diabetes prevention and reversal (not directly insulin thermostability), as well as receiving an independent award from the Novo Nordisk Foundation. MAA is also President of Insulin for Life USA. All other authors declare no competing interests.
Comment in
-
Real-world insulin stability and global access.Lancet Diabetes Endocrinol. 2023 May;11(5):307-309. doi: 10.1016/S2213-8587(23)00066-9. Epub 2023 Mar 29. Lancet Diabetes Endocrinol. 2023. PMID: 37003281 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical